AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8518020 — intervention group
Group type: EXPERIMENTAL
Intervention: SMF
Number of subjects: 153
Study 8518020 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 153
Study 8518020 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 153
Study 3120329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium deoxycholate preoperatively
Number of subjects: 46
Study 3120329 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid
Number of subjects: 46
Study 3120329 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 30888202 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0
Study 30888202 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 0
Study 27451920 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing for Life intervention (biweekly visits from mentors from pregnancy until age 5 years and parent training at age 2 years)
Number of subjects: 233
Study 27451920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 233
Study 27451920 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing for Life intervention
Number of subjects: 233
Study 25637151 — intervention group
Group type: EXPERIMENTAL
Intervention: Benson's relaxation technique (audiotape listened to twice a day for 20 minutes for 8 weeks)
Number of subjects: 86
Study 25637151 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 86
Study 23013888 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (morning-dose group)
Number of subjects: 218
Study 23013888 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (evening-dose group)
Number of subjects: 218
Study 21273901 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hr wheelchair workshop
Number of subjects: 24
Study 21273901 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 19682654 — intervention group
Group type: EXPERIMENTAL
Intervention: 780-nm laser phototherapy
Number of subjects: 0
Study 19682654 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser irradiation in cell cultures
Number of subjects: 0
Study 19682654 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment initiated at the earliest possible stage post injury
Number of subjects: 0
Study 17062304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine capsules (8 mg) administered with food
Number of subjects: 96
Study 17062304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine tablets (8 mg) administered with food
Number of subjects: 96
Study 17062304 — intervention group
Group type: COMPARATOR
Intervention: Tizanidine capsules (8 mg) administered in fasting state
Number of subjects: 96
Study 17062304 — intervention group
Group type: COMPARATOR
Intervention: Tizanidine tablets (8 mg) administered in fasting state
Number of subjects: 96
Study 12932798 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 23
Study 12932798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline (56.25 mg)
Number of subjects: 23
Study 12932798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10636414 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 1.5 mU/kg per minute
Number of subjects: 9
Study 10636414 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 3 mU/kg per minute
Number of subjects: 9
Study 10636414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8864546 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous neuropeptide Y (NPY) 50 nmol
Number of subjects: 7
Study 8864546 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous neuropeptide Y (NPY) 100 nmol
Number of subjects: 7
Study 8864546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal pretreatment with NPY (20 nmol)
Number of subjects: 7
Study 8864546 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study 8864546 — intervention group
Group type: COMPARATOR
Intervention: Oxymetazoline (20 nmol)
Number of subjects: 7
Study 1346819 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibodies (aCEPHA and aCL)
Number of subjects: 597
Study 6397949 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision plus curettage and primary suture under antibiotic cover
Number of subjects: 83
Study 6397949 — intervention group
Group type: COMPARATOR
Intervention: Conventional incision and drainage
Number of subjects: 83
Study 29364026 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week progressive home intrinsic foot muscle (IFM) exercise program performed daily
Number of subjects: 24
Study 29364026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 28419379 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of local anesthetic to myofascial trigger points (MTrPs)
Number of subjects: 31
Study 26869680 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28
Study 26869680 — intervention group
Group type: COMPARATOR
Intervention: Low-to-Moderate Intensity Exercise (LMIE)
Number of subjects: 28
Study 26869680 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HIIT and LMIE
Number of subjects: 28
Study 25122980 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing calcium hydroxyapatite
Number of subjects: 107
Study 25122980 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum (control)
Number of subjects: 107
Study 23029823 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aspiration
Number of subjects: 45
Study 23029823 — intervention group
Group type: COMPARATOR
Intervention: Catheter drainage
Number of subjects: 45
Study 20618973 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical model adjusted for differences in study arms
Number of subjects: 0
Study 20618973 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted results for combined studies
Number of subjects: 0
Study 20618973 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregate study values adjustment
Number of subjects: 0
Study 20618973 — intervention group
Group type: EXPERIMENTAL
Intervention: Downweighting method 1
Number of subjects: 0
Study 20618973 — intervention group
Group type: EXPERIMENTAL
Intervention: Downweighting method 2
Number of subjects: 0
Study 20618973 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised studies alone
Number of subjects: 0
Study 20618973 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomised studies alone
Number of subjects: 0
Study 17215177 — intervention group
Group type: EXPERIMENTAL
Intervention: Water soluble calcium hydroxycitrate (HCA) as Garcinia atroviridis
Number of subjects: 50
Study 17215177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15543337 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamins (5 mg folic acid, 0.4 mg hydroxycobalamin and 50 mg pyridoxine) daily for 8 weeks
Number of subjects: 123
Study 15543337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 11919401 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes duration
Number of subjects: 98
Study 11919401 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal proteinuria
Number of subjects: 98
Study 9598714 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling + cognitive-behavioral mood management (CBT)
Number of subjects: 29
Study 9598714 — intervention group
Group type: COMPARATOR
Intervention: Behavioral counseling (BC)
Number of subjects: 29
Study 9124839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (1,000 mg)
Number of subjects: 832
Study 9124839 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 832
Study 2174933 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated chemoembolization with gelfoam powder and doxorubicin (group 1)
Number of subjects: 42
Study 2174933 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment (group 2)
Number of subjects: 42
Study 7013960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with diethylstilbestrol, cyclophosphamide, and 5‐fluorouracil (DES + CTx + FU)
Number of subjects: 87
Study 7013960 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy (DES leads to CTx + FU)
Number of subjects: 87
Study 7013960 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 87
Study 31907006 — intervention group
Group type: EXPERIMENTAL
Intervention: 120,000 IU/month of vitamin D (cholecalciferol) for 6 months
Number of subjects: 0
Study 31907006 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for 6 months
Number of subjects: 0
Study 31094991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary (IM) nailing
Number of subjects: 30
Study 31094991 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 30
Study 29029644 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month dispensing of ART
Number of subjects: 8200
Study 29029644 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month dispensing of ART
Number of subjects: 8200
Study 29029644 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 8200
Study 24108196 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal cholecystectomy (TVC)
Number of subjects: 40
Study 24108196 — intervention group
Group type: COMPARATOR
Intervention: Needlescopic cholecystectomy (NC)
Number of subjects: 40
Study 24131035 — intervention group
Group type: EXPERIMENTAL
Intervention: Secular song reminiscence (n=13)
Number of subjects: 40
Study 24131035 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious song reminiscence (n=13)
Number of subjects: 40
Study 24131035 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard story reminiscence (n=14)
Number of subjects: 40
Study 22456300 — intervention group
Group type: EXPERIMENTAL
Intervention: semagacestat 140 mg
Number of subjects: 54
Study 22456300 — intervention group
Group type: EXPERIMENTAL
Intervention: semagacestat 280 mg
Number of subjects: 54
Study 22456300 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study 20139231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg/d)
Number of subjects: 20
Study 20139231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18084118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 101
Study 18084118 — intervention group
Group type: COMPARATOR
Intervention: Control (no pitavastatin)
Number of subjects: 101
Study 16238507 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined meditation and massage
Number of subjects: 58
Study 16238507 — intervention group
Group type: COMPARATOR
Intervention: Meditation
Number of subjects: 58
Study 16238507 — intervention group
Group type: COMPARATOR
Intervention: Massage
Number of subjects: 58
Study 16238507 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 58
Study 11851662 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 300
Study 11851662 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 300
Study 10440399 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) treatment aimed at three predefined target MPA AUC values (16.1, 32.2, and 60.6 microg x hr/ml)
Number of subjects: 154
Study 10440399 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) treatment
Number of subjects: 154
Study 10440399 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 154
Study 7799083 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐sestamibi imaging
Number of subjects: 72
Study 7799083 — intervention group
Group type: COMPARATOR
Intervention: Control group (gender-matched subjects with low pre-test likelihood of CAD)
Number of subjects: 72
Study 1980464 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 0
Study 1980464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg
Number of subjects: 0
Study 1980464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 2 mg
Number of subjects: 0
Study 1980464 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs (Lormetazepam and Flurazepam)
Number of subjects: 0
Study 1980464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 367976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 110
Study 367976 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 110
Study 28865911 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Management Therapy (TMT; VRET plus a group treatment for anger, depression, and social isolation)
Number of subjects: 92
Study 28865911 — intervention group
Group type: COMPARATOR
Intervention: VRET plus a psychoeducation control condition
Number of subjects: 92
Study 29336615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornibel® (etonogestrel/ethinylestradiol 11.00/3.47 mg)
Number of subjects: 40
Study 29336615 — intervention group
Group type: COMPARATOR
Intervention: Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg)
Number of subjects: 40
Study 26118527 — intervention group
Group type: EXPERIMENTAL
Intervention: Self myofascial release (SMR) via a tennis ball to the plantar aspect of the foot
Number of subjects: 24
Study 26118527 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 24
Study 23812209 — intervention group
Group type: EXPERIMENTAL
Intervention: NexGen LPS Gender Solutions (GS) prosthesis
Number of subjects: 80
Study 23812209 — intervention group
Group type: COMPARATOR
Intervention: NexGen LPS Flex (ST) prosthesis
Number of subjects: 80
Study 21820719 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mM glucose (Group A)
Number of subjects: 4
Study 21820719 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mM glucose (Group B)
Number of subjects: 4
Study 21820719 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mM G3P with 0.15 mM glucose (Group C)
Number of subjects: 4
Study 21820719 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.34 mM citrate with 2.77 mM myo‐inositol (Group D)
Number of subjects: 4
Study 19493153 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD plus appropriate medical therapy
Number of subjects: 1550
Study 19493153 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 1550
Study 17074344 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (0.2 mg)
Number of subjects: 60
Study 17074344 — intervention group
Group type: COMPARATOR
Intervention: rhCG (250 microg)
Number of subjects: 60
Study 15543464 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoelectric control strategy using MES from wrist flexor and extensor muscles
Number of subjects: 7
Study 12101821 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise and low fat diet (walking 60 minutes daily, <20% total fat, 300 mg/d cholesterol)
Number of subjects: 62
Study 12101821 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise and low fat diet
Number of subjects: 62
Study 9773699 — intervention group
Group type: EXPERIMENTAL
Intervention: ISBPB with 10 mL 0.125% bupivacaine with epinephrine 1:400,000 (n = 15)
Number of subjects: 30
Study 9773699 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (n = 15)
Number of subjects: 30
Study 9791777 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 60
Study 9791777 — intervention group
Group type: COMPARATOR
Intervention: Standard approach to postoperative analgesia (intramuscular injections on an 'as needed' basis)
Number of subjects: 60
Study 2201481 — intervention group
Group type: EXPERIMENTAL
Intervention: Clovoxamine
Number of subjects: 0
Study 2201481 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 2201481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 410298 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Rho(D) immune globulin (human)
Number of subjects: 0
Study 410298 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up testing of immune globulin
Number of subjects: 0
Study 410298 — intervention group
Group type: EXPERIMENTAL
Intervention: Single low-dose immune globulin preparations
Number of subjects: 0
Study 31225625 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content cigarettes (0.4, 2.4, 5.2, 15.8 mg/g)
Number of subjects: 169
Study 31225625 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content cigarettes
Number of subjects: 169
Study 30966820 — intervention group
Group type: COMPARATOR
Intervention: Preserved LVEF (LVEF ≥ 50%)
Number of subjects: 6198
Study 30966820 — intervention group
Group type: COMPARATOR
Intervention: Mid-range reduced LVEF (LVEF 40-49%)
Number of subjects: 6198
Study 30966820 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced LVEF (LVEF < 40%)
Number of subjects: 6198
Study 26361969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg oral, twice a day for a maximum of 4 years)
Number of subjects: 1114
Study 26361969 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice a day for a maximum of 4 years)
Number of subjects: 1114
Study 26361969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 1114
Study 26361969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1114
Study 23574730 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (150 mg/day)
Number of subjects: 35
Study 23574730 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (50 mg/day)
Number of subjects: 35
Study 20880294 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 144
Study 20880294 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 144
Study 20880294 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 144
Study 20880294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 18449573 — intervention group
Group type: EXPERIMENTAL
Intervention: Double lumen totally implantable subcutaneous port system (PORT)
Number of subjects: 32
Study 18449573 — intervention group
Group type: COMPARATOR
Intervention: Double lumen central venous catheter (CVC)
Number of subjects: 32
Study 17109447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (35 mg/m2) and gemcitabine (1000 mg/m2) with paclitaxel (70 mg/m2)
Number of subjects: 66
Study 17109447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (35 mg/m2) and gemcitabine (1000 mg/m2) with vinorelbine (25 mg/m2)
Number of subjects: 66
Study 15701228 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuli presented to the right cerebral hemisphere during individuation tasks.
Number of subjects: 2
Study 15701228 — intervention group
Group type: COMPARATOR
Intervention: Stimuli presented to the left cerebral hemisphere during individuation tasks.
Number of subjects: 2
Study 15701228 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging investigation of individuation tasks.
Number of subjects: 2
Study 11723527 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg administered twice daily via a breath‐activated, multi‐dose, dry‐powder inhaler
Number of subjects: 43
Study 11723527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9387000 — intervention group
Group type: EXPERIMENTAL
Intervention: False feedback of wheezing
Number of subjects: 90
Study 9387000 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet respiratory sounds
Number of subjects: 90
Study 9387000 — intervention group
Group type: COMPARATOR
Intervention: No sound
Number of subjects: 90
Study 7898966 — intervention group
Group type: EXPERIMENTAL
Intervention: New radiographic scoring system for bronchopulmonary dysplasia (BPD)
Number of subjects: 366
Study 7898966 — intervention group
Group type: COMPARATOR
Intervention: Edwards score
Number of subjects: 366
Study 7898966 — intervention group
Group type: EXPERIMENTAL
Intervention: New radiographic scoring system for BPD
Number of subjects: 366
Study 7898966 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal corticosteroid use
Number of subjects: 366
Study 2730857 — intervention group
Group type: EXPERIMENTAL
Intervention: NODS 40 micrograms
Number of subjects: 8
Study 2730857 — intervention group
Group type: EXPERIMENTAL
Intervention: NODS 80 micrograms
Number of subjects: 8
Study 2730857 — intervention group
Group type: EXPERIMENTAL
Intervention: NODS 170 micrograms
Number of subjects: 8
Study 2730857 — intervention group
Group type: COMPARATOR
Intervention: Conventional eyedrop (2% Minims, 518 micrograms)
Number of subjects: 8
Study 2730857 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of total doses delivered
Number of subjects: 8
Study 30133324 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery from disuse in healthy men after 1-leg cast immobilization and reloading.
Number of subjects: 0
Study 30133324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mice undergoing reloading after hindlimb suspension.
Number of subjects: 0
Study 27906554 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) in the evening
Number of subjects: 0
Study 27906554 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) in the morning
Number of subjects: 0
Study 25875541 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed (37°C), humidified (98%) insufflation carbon dioxide
Number of subjects: 82
Study 25875541 — intervention group
Group type: COMPARATOR
Intervention: Standard gas (19°C, 0%)
Number of subjects: 82
Study 23161124 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program
Number of subjects: 100
Study 23161124 — intervention group
Group type: COMPARATOR
Intervention: Usual health care
Number of subjects: 100
Study 21538524 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (up to 2000 mg per day)
Number of subjects: 16
Study 21538524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21538524 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 16